Амантадин при болезни Паркинсона современные возможности долговременной терапии

@inproceedings{2018,
  title={Амантадин при болезни Паркинсона современные возможности долговременной терапии},
  author={В. В. Полещук and Сергей Николаевич Иллариошкин},
  year={2018}
}
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied by the fluctuations in symptoms and dyskinesia, and these complications are an extremely important factor that adversely affects the quality of life. The hyperactivity of glutamate NMDA receptors of the striatum plays an important role in the pathophysiology of medicinal dyskinesia, so the use of anti-glutamatergic agents, primarily amantadine, is currently the common method of combating… CONTINUE READING